Track topics on Twitter Track topics that are important to you
Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the design, development and commercialization of a long-term, implantable continuous glucose monitoring (CGM) system for people with diabetes, today reported financial results for the quarter ended March 31, 2019.
RECENT HIGHLIGHTS & ACCOMPLISHMENTS:
“We are pleased with our progress this year, which is marked by growing interest and support of Eversense from users, prescribers and payors,” said Tim Goodnow, President and Chief Executive Officer of Senseonics. “We are seeing meaningful growth in both covered lives and new users through our European partners. In the U.S., the launch of the Eversense Bridge Patient Access Program is simplifying the reimbursement process for new patients and supporting their ability to act on the interest we see across patients and providers. It is also enabling additional opportunities to get in front of the largest national payors. Through constructive experiences with these payors, we believe that we will obtain additional positive coverage decisions in the future. We are looking forward to building on this momentum.”
FIRST QUARTER 2019 RESULTS:
Revenue was $3.4 million for the first quarter of 2019 including adjustments for the bridge program, compared to $2.9 million for the first quarter of 2018.
First quarter 2019 gross profit decreased by $2.9 million year-over year, to ($3.3) million. The decrease in gross profit was associated with one-time component obsolescence due to product upgrades and product expiry due to the timing of the extension of the company’s distribution agreement with Roche.
First quarter 2019 sales and marketing expenses increased $9.4 million year-over year, to $12.8 million. The increase in sales and marketing expenses was primarily driven by the build out of the U.S. salesforce.
First quarter 2019 research and development expenses decreased $1.0 million year-over-year, to $7.1 million. The decrease in research and development expenses was primarily driven by the completion of all activities associated with the U.S. PMA Panel meeting for Eversense.
First quarter 2019 general and administrative expenses increased $2.5 million, year-over-year, to $6.5 million. The increase in general and administrative expenses was primarily driven by an increase in compensation, legal and other administrative expenses associated with supporting operational growth.
Net loss was $29.4 million, or $0.17 per share, in the first quarter of 2019, compared to $22.3 million, or $0.16 per share, in the first quarter of 2018.
As of March 31, 2019, cash and cash equivalents were $103.7 million and outstanding indebtedness was $65.2 million.
2019 Financial Outlook
Revenue for full year 2019 is expected to be in the range of $25 to $30 million.
CONFERENCE CALL AND WEBCAST INFORMATION
Company management will host a conference call at 4:30 pm (Eastern Time) today, May 9, 2019, to discuss these financial results and recent business developments. This conference call can be accessed live by telephone or through Senseonics’ website.
Live Teleconference Information:
Live Webcast Information:
Senseonics Holdings, Inc. is a medical technology company focused on the design, development and commercialization of transformative glucose monitoring products designed to help people with diabetes confidently live their lives with ease. From its inception, Senseonics has been advancing the integration of novel, fluorescence sensor technology with smart wearable devices. The Eversense® CGM System received PMA approval from the FDA for up to 90 days of continuous use and is available in the United States. The Eversense® XL CGM System received CE mark for up to 180 days of continuous use and is available in Europe. For more information on Senseonics, please visit www.senseonics.com.
FORWARD LOOKING STATEMENTS
Any statements in this press release about future expectations, plans and prospects for Senseonics, including statements about the potential additional positive coverage decisions, the potential commercialization of Eversense in additional markets, Senseonics’ projected revenue for full year 2019, the ongoing commercialization of Eversense in the U.S. and Eversense XL in Europe, growing patient and clinician demand for Eversense, and the potential life-enhancing benefits Eversense offers people with diabetes, and other statements containing the words “believe,” “expect,” “intend,” “may,” “projects,” “will,” and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: uncertainties in the development and regulatory approval processes, uncertainties inherent in the commercial launch and commercial expansion of the product, and such other factors as are set forth in the risk factors detailed in Senseonics’ Annual Report on Form 10-K for the year ended December 31, 2018, Senseonics’ Quarterly Report on Form 10-Q for the quarter ended March 31, 2019, and Senseonics’ other filings with the SEC under the heading “Risk Factors.” In addition, the forward-looking statements included in this press release represent Senseonics’ views as of the date hereof. Senseonics anticipates that subsequent events and developments will cause Senseonics’ views to change. However, while Senseonics may elect to update these forward-looking statements at some point in the future, Senseonics specifically disclaims any obligation to do so except as required by law. These forward-looking statements should not be relied upon as representing Senseonics’ views as of any date subsequent to the date hereof.
|Senseonics Holdings, Inc.|
|Condensed Consolidated Balance Sheets|
|(in thousands, except share and per share data)|
|March 31,||December 31,|
|Cash and cash equivalents||$||103,675||$||136,793|
Accounts receivable (primarily from a related party)
|Prepaid expenses and other current assets||4,698||3,985|
|Total current assets||125,110||158,106|
|Deposits and other assets||114||117|
|Property and equipment, net||2,046||1,750|
|Right of use asset, building||2,131||—|
|Liabilities and Stockholders’ Equity|
|Accrued expenses and other current liabilities||13,754||13,851|
|Right of use liability, building, current portion||431||—|
|Term Loans, current portion||10,000||10,000|
|Total current liabilities||27,459||28,886|
|Term Loans, net of discount and current portion||2,347||4,783|
|2023 Notes, net of discount||36,949||36,103|
|Term Loans, accrued interest||1,892||1,764|
|Right of use liability, building, net of current portion||1,791||—|
Common stock, $0.001 par value per share; 450,000,000 shares authorized; 176,958,487 and 176,918,381 shares issued and outstanding as of March 31, 2019 and December 31, 2018
|Additional paid-in capital||430,926||428,878|
|Total stockholders' equity||43,944||71,261|
|Total liabilities and stockholders’ equity||$||129,401||$||159,973|
|Senseonics Holdings, Inc.|
|Unaudited Condensed Consolidated Statements of Operations and Comprehensive Loss|
|(in thousands, except share and per share data)|
|Three Months Ended|
|Revenue, primarily from a related party||$||3,423||$||2,946|
|Cost of sales||6,733||3,308|
|Sales and marketing expenses||12,834||3,441|
|Research and development expenses||7,108||8,113|
|General and administrative expenses||6,516||4,011|
|Other income (expense), net:|
|Change in fair value of derivative liability||2,072||(4,847||)|
|Other (expense) income||(262||)||88|
|Total other income (expense), net||403||(6,346||)|
|Total comprehensive loss||$||(29,365||)||$||(22,273||)|
|Basic and diluted net loss per common share||$||(0.17||)||$||(0.16||)|
|Basic and diluted weighted-average shares outstanding||176,954,116||137,069,008|
Lynn Lewis or Philip Taylor
The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...